Sangamo BioSciences, Inc. announced today the presentation of data demonstrating that human CD4 T-cells can be made permanently resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)) and preferentially survive and expand in an animal after HIV infection. The presentation, entitled, "Establishment of HIV Resistant CD4 T-Cells by Engineered Zinc Finger Protein Nucleases" is taking place today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago.
"The positive results being presented at ICAAC continue to strengthen our belief that CCR5-ZFNs are an important and promising class of anti-HIV compounds and may represent a "next generation" of HIV-entry blocking agents," said Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, and a co-author of the study. "I look forward to working with Sangamo to bring this program into the clinic as quickly as possible."
read more
Wednesday, September 19, 2007
HIV/AIDS vaccination 'within a decade'
Sir Gustav, Australian of the Year in 2000, said scientists were making real progress on the creation of the potentially life-saving vaccines.
"I have no doubt that vaccinations for the big three will be found in the next decade,'' Sir Gustav said.
The Florey Medical Research Foundation is a fundraising arm of the university's medical division.
The Austrian-born scientist is well known for his humanitarian work, promoting Aboriginal reconciliation and projects for the World Health Organisation and the Bill and Melinda Gates Foundation.
He holds an array of international scientific awards and doctorates, including a breakthrough in modern immunology for which he was knighted in 1977. read more
"I have no doubt that vaccinations for the big three will be found in the next decade,'' Sir Gustav said.
The Florey Medical Research Foundation is a fundraising arm of the university's medical division.
The Austrian-born scientist is well known for his humanitarian work, promoting Aboriginal reconciliation and projects for the World Health Organisation and the Bill and Melinda Gates Foundation.
He holds an array of international scientific awards and doctorates, including a breakthrough in modern immunology for which he was knighted in 1977. read more
HIV prevention could save millions in Africa - study
Using drugs to prevent HIV infection could prevent as many as 3 million new cases in Africa if it was done right, researchers predicted on Tuesday.
A daily pill would not even have to prevent infection all the time to have this effect, if it was given to the right people with the proper counseling, the team at the University of Pittsburgh School of Medicine and at Imperial College London said.
"If you do it right, you can prevent lots of infections," Pittsburgh's Dr. John Mellors, who helped direct the study, said in a telephone interview.
The researchers wanted to know if a potential new approach called pre-exposure chemoprophylaxis, or PrEP, would work in a real-world setting.
read more
A daily pill would not even have to prevent infection all the time to have this effect, if it was given to the right people with the proper counseling, the team at the University of Pittsburgh School of Medicine and at Imperial College London said.
"If you do it right, you can prevent lots of infections," Pittsburgh's Dr. John Mellors, who helped direct the study, said in a telephone interview.
The researchers wanted to know if a potential new approach called pre-exposure chemoprophylaxis, or PrEP, would work in a real-world setting.
read more
J&J says Prezista matches Kaletra in HIV trial
Johnson & Johnson said on Tuesday its drug Prezista was as effective in a late-stage trial as Abbott Laboratories Inc's Kaletra in cutting HIV to undetectable levels among patients not previously treated with HIV drugs.
Prezista, a once-daily protease inhibitor recently introduced by J&J, was given to patients along with Abbott's older protease inhibitor Norvir (ritonavir) and Gilead Science Inc's widely used Truvada. Truvada itself contains two drugs belonging to a separate class of HIV treatments called nucleoside reverse transcriptase inhibitors.
read more
Prezista, a once-daily protease inhibitor recently introduced by J&J, was given to patients along with Abbott's older protease inhibitor Norvir (ritonavir) and Gilead Science Inc's widely used Truvada. Truvada itself contains two drugs belonging to a separate class of HIV treatments called nucleoside reverse transcriptase inhibitors.
read more
Pfizer says long-term data shows safety and efficacy of HIV drug Selzentry
Pfizer (NYSE:PFE) Inc said that nearly three times as many patients receiving Selzentry, in addition to an optimised background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimised regimen alone.
'These data continue to demonstrate that Selzentry provides significant benefit to certain treatment-experienced patients,' said Dr Jacob Lalezari, director, Assistant Clinical Professor of Medicine at the University of California, San Francisco.
'The safety and durability of response seen with Selzentry out to one year in our study is reassuring. This drug is an important new weapon for clinicians who treat HIV,' he added.
Results from the planned 48-week analysis also demonstrated that Selzentry, along with an optimised background regimen, significantly increased CD4 cells, as compared to patients receiving an optimised regimen alone read more
'These data continue to demonstrate that Selzentry provides significant benefit to certain treatment-experienced patients,' said Dr Jacob Lalezari, director, Assistant Clinical Professor of Medicine at the University of California, San Francisco.
'The safety and durability of response seen with Selzentry out to one year in our study is reassuring. This drug is an important new weapon for clinicians who treat HIV,' he added.
Results from the planned 48-week analysis also demonstrated that Selzentry, along with an optimised background regimen, significantly increased CD4 cells, as compared to patients receiving an optimised regimen alone read more
Daily anti-HIV pill could save millions from infection: study
Providing healthy people with an antiretroviral drug to protect them against HIV infection could drastically slow the spread of the virus in sub-Saharan Africa, US researchers said Tuesday.
In a best-case scenario, the drug could prevent three million new HIV cases in this part of Africa over a 10-year span, even if it was only made available to the most sexually active individuals, the investigators said.
"This could represent another tool in our arsenal against HIV infection," said Ume Abbas, an assistant professor of medicine at the University of Pittsburgh School of Medicine and lead author of the paper
read more
In a best-case scenario, the drug could prevent three million new HIV cases in this part of Africa over a 10-year span, even if it was only made available to the most sexually active individuals, the investigators said.
"This could represent another tool in our arsenal against HIV infection," said Ume Abbas, an assistant professor of medicine at the University of Pittsburgh School of Medicine and lead author of the paper
read more
Accidental HIV victim ponders legal steps
The oldest of 42 HIV-positive South African babies and children with HIV-negative parents, the 16-year-old now wants her mother to take Western Cape health authorities to court over her suspected accidental infection "so that this can't happen to anyone else".
Sarah's family have no idea how she was infected but believe she may have been treated with unsterilised medical equipment while in hospital for TB treatment. Other cases of suspected accidental HIV-infection have been linked to expressed breast milk being given to HIV-negative babies, and dirty syringes in state hospitals.
read more
Sarah's family have no idea how she was infected but believe she may have been treated with unsterilised medical equipment while in hospital for TB treatment. Other cases of suspected accidental HIV-infection have been linked to expressed breast milk being given to HIV-negative babies, and dirty syringes in state hospitals.
read more
Subscribe to:
Posts (Atom)
